Use of miR145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer. Zhu J, Qin P, Cao C, Dai G, et al. Oncol Rep 2021;45:963-974.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhu J, Qin P, Cao C, Dai G, et al. Use of miR145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer. Oncol Rep 2021;45:963-974.
PMID: 33650661